In December 2005, bases of chemical compounds of natural origin have been gathered within the “chemical library” project in order to find new hits, including anti-bacterial virulence for MUTABILIS.
This project was funded by the Regional Council of Ile-de-France, the General Council of Seine-Saint-Denis and labeled by the Medicen competitiveness cluster.
In January 2006, Mutabilis began its work on the European “Dynamic Interactive Chemical Biology and Biomedecine” program which enabled it to lay the groundwork for his research in anti-bacterial virulence.
In 2008, funding from the European Union is obtained for the HIV-ACE project or “Targeting assembly of infectious viruses”, which includes eight partners throughout Europe. It develops antivirals based on new mechanisms of action, specifically targeting the capside and the envelope of the HIV.
In 2010, MUTABILIS is the coordinator of the ANR IN-AIDS project: “Preclinical Development of innovative anti-HIV molecules – Integration targeting integrase-LEDGF interaction” involving two teams from the CNRS and IGBMC to develop new molecules targeting integrase.
In 2012, MUTABILIS is also coordinator of the FP7 HIVINNOV consortium subsidized up to 6M€ by the European Union. This anti-retroviral discovery project gathers world leaders in HIV research:
• The laboratory of Pr. Ariberto Fassati, University College London (ULC) (Great Britain).
• The laboratory of Pr. Peter Cherepanov, Cancer Research UK (CRUK) (UK).
• The laboratory of Pr. Benjamin Berkhout of Academisch Medical Center bij de Universiteit van Amsterdam (Netherlands).
• The laboratory of Pr. Jose Gatell, the Fundació per la Recerca Biomedica (FCRB) Univ. of Barcelona (Spain).
• The laboratory of Dr. Stephane Emiliani, Cochin Institute (INSERM CNRS), Paris (France).
• The laboratory of Pr. Saheb Ali and Dr. Alessia Zamborlini, Hôpital St-Louis (INSERM CNRS), Paris (France).
Additional funding was also received through several grants including ANR, ANRS and repayable funds from BPI.